EF Hutton initiated coverage of Carisma Therapeutics (CARM) with a Buy rating and $24 price target Carisma may be the company that creates the first solid tumor CAR therapy using macrophages, the analyst tells investors in a research note. The firm says the company is also working with Moderna to develop an in-vivo CAR-M therapeutic. Success can potentially transform the CAR landscape as we know it today, contends EF.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.